DIAMOND BIOFUND - Key Persons

Andrew Chang joint in Cathay Financial Holdings group in 2016 as Executive Vice President at Cathay Securities Corp., leading the research team in global healthcare, consumer and technology fields. He was assigned as Portfolio Manager and head of healthcare research at Cathay Securities Investment trust in October, 2018. Before that, he was the equity analyst covering Asian Information and Communication Technology (ICT) and Video Surveillance sectors, specializing in Apple Supply Chains, at Macquarie and Deutsche Bank since 2010. Andrew also led Investor Relations at Acer Inc. with his over 10-year experience in PC and notebook industry. He graduated from National Taiwan University with Master degree of International Business, Global Finance (MBA).

Job Titles:

• Chairman and Co - Founder of Pharmacodia

Dr. Jing Li is the Chairman and co-founder of Pharmacodia. Pharmacodia is a world leader in bio big data area. It is the first medical big data company to provide a platform to cover all discovery needs of the pharmaceutical research: 1) first one-stop integrated pharma big data platform of drug R&D in the world. 2) front runner in industry , data covered beyond current leaders such as INTERGRITY & PHARMAPROJECT. 3) the first ever DATAbase to cover preclinical data of NCE up to 600+. 4) mobile devices and Web application.

Job Titles:

• Founder and Chairman of China Entrepreneurs Forum
• Founding Partner of YuanMing Capital

Dr. Lawrence Tian is a Founding Partner of YuanMing Capital. YuanMing Capital focuses on the investment in pharmaceutial research and development, innovative medical devices and high-end medical services in both China and the United States. YuanMing has successfully invested in a dozen of leading biopharma companies including BeiGene, Ascentage Pharma, Mevion Medical Systems, Pharmacodia, CF PharmTech, JW Theraperutics, Adlai Nortye and Digital China Health. Prior to founding YuanMing Capital, Dr. Tian established China International Futures Corporation, co-founded Wu Mart Supermarket and Yabuli Ski Resort. He also served as Chairman of China Chengtong Group. Since 2010, Dr. Tian has been committed to promoting China's capital investment into US life science innovative companies, and has accumulated solid experiences and an outstanding track record. Dr. Tian is the Founder and Chairman of China Entrepreneurs Forum and China-U.S. Business Leaders Roundtable. As a core organizer of various high-end meeting for entrepreneurs of both countries, Dr. Tian is an influential figure in the Sino-China business scene and has extensive social influence. He serves as the Chairman of Investment Committee of China Pharmaceutical Industry Research and Development Association, and he is a member of the Biotech Advisory Panel of the Stock Exchange of Hong Kong Limited ("HKEX"). Dr. Tian obtained his master's degree and doctoral degree from Wuhan University. He was the recipient of China's highest prize for economics: China Economics Theory Innovation Award.

Job Titles:

• Freelance Writer for Healthcare Executive
• Honorary Director of ACLSTA

Ms. Sammy (Chinese name: Hua Jiang) is currently the Vice President of Luye Pharma Group, responsible for corporate strategy, business development and Investor relationship. Ms. Jiang has over 19 years of experience in pharmaceutical industry. Ms. Jiang holds a Doctor of Business Administration from United Business Institute, a Master's degree in Business Administration from KEDGE Business School (previously known as Euromed Management School), and a Bachelor's degree of Economics from Economy School, Fudan University. She is also an economist certified by the Ministry of Human Resources and Social Security of the People's Republic of China. Ms. Jiang is the honorary director of ACLSTA (American Chinese Life Science Technology Association) and Vice Chairman of KEDGE AEMBA Alumni Association. She was listed in "China Top 99 Pharma Executives" in 2010, and continuous 3 years win "the national excellent award" by SAPA (Sino America pharmaceutical association) since 2010. Ms. Jiang is the freelance writer for Healthcare executive magazine, China Pharmaceutical technology economics and management magazine, etc. She had been invited to attend and make the speech in some related seminar/conference. She is also the Program Professor for Yeehong Business School, Shenyang Pharmaceutical University and Yantai University Pharmaceutical College.

Job Titles:

• Managing Director, Head of Life Science Investments, of Taiwania Capital Management Company

Jerome Shen, Ph.D., is the Managing Director, Head of Life Science Investments, of Taiwania Capital Management Company. Prior to joining Taiwania, he was the President and co-founder of Allgenesis Biotherapeutics Inc., a new drug development company addressing the unmet medical needs in the central nervous system and ophthalmology areas since 2014. He played the executive management roles of the venture capital firms, including Cheng Xin Ventures and Xinchen Ventures, having 20 year venture investment experience in the life science and biotech/pharmaceutical industry. He has intensive and extensively working experiences with bio-scientific entrepreneurs to help grow the corporates' value. In addition to the venture capital businesses, he also took the leading management roles in several biotech start-ups, responsible for corporate development and strategic initiatives and planning. Dr. Shen was the Secretary General of Taiwan Biotech Association, a non-for-profit organization, from 2005 to 2008. The Biotech Association was to provide services to the members in business development, human resources, and training programs. He received his Ph.D. in Chemical Engineering at the University of Wisconsin, Madison.

Before joining Taishin Securities, Mr. Guo was Managing Director and headed UBS Investment Banking business in Taiwan. Mr. Guo has more than 26 years' investment banking experience across a broad range of banking practices, including major international capital market, derivatives, M&A and financial sponsors' transactions. He executed the transactions for leading business groups in Taiwan, e.g. Formosa, Fubon, Cathay, Chunghwa Telecom, China Steel, Uni-President, AUO, Hon Hai, Asus, LiteOn, Wistron, Compal and Carlyle. He also completed major Taiwan enterprises HK IPO transactions, such as Sun-Art, Uni-President China, Want Want and Foxconn. In addition, he involved in key Taiwan financial industry M&A transactions, such as New Bridge/Taishin, Standard Charter/Hsinchu Bank, Sinopac/IBT, Temasek/Esun, DBS/Bowa, Carlyle/Tachong, Tachong/Yuanta.

Job Titles:

• Managing Director
• Managing Director of Quan Capital

Managing Director, Quan Capital Dr. Marietta Wu is Managing Director of Quan Capital, a life sciences venture fund with offices in China & US, and deep expertise in cross-border value creation and global investments. She is a founding member of Zai Lab and served as COO of the company prior to Quan Capital. Zai Lab is a NASDAQ listed company widely recognized as a leader in bringing innovative and transformative medicines to China. Over the past decade, Dr. Wu has been active in cross-border ventures and value creation in the life sciences industry. She was Managing Director at Burrill & Company, leading Burrill's investments and operation in Greater China, focusing on venture capital investing in China and Taiwan related life sciences opportunities. She was a board member of Zai Lab Limited (NASDAQ: ZLAB), JHL Biotech (TWEM: 6540), Taiwan Liposome Company (GTSM: 4152) and General Biologics Corporation (TWEM: 4117). She also served as acting COO of Waterstone, a specialty pharmaceutical company with key operations in China. Dr. Wu is a frequent speaker and author on China and Taiwan life sciences topics, and a founding member of the China Healthcare Investment Conference. Prior to her focus on healthcare investments and company building, Dr. Wu was Director of Strategy at Edwards Lifesciences. She also held various financial and business development positions at Eli Lilly & Company. Dr. Wu received her medical degree from Shanghai Jiaotong University School of Medicine (formerly Shanghai Second Medical University), a Ph.D. in Medical Sciences from Medical College of Ohio, and an MBA from the University of Michigan Ross School of Business.

Mr. David Dunn currently serves in the United States as Practice Lead and Scientific Advisor. He has more than 20 years of experience in biotechnology-related industries, and has worked in pharmaceutical companies such as Pfizer and as a lecturer at Harvard Medical School.

Job Titles:

• Chief Financial Officer
• EVP

Mr. George Lin, J.D., a healthcare veteran brings with him over 20 years of investment banking and legal experience working with numerous private and public companies globally. Prior to joining Hua Medicine, he was Asia Pacific Head of Consumer, Retail and Healthcare Investment Banking and Head of Hong Kong and Taiwan Investment Banking for Bank of America Merrill Lynch based in Hong Kong. As an investment banker and corporate lawyer focused on healthcare, retail and the consumer sectors, Mr. Lin was previously based in Los Angeles and San Francisco before moving to Hong Kong in 2007. His experience entails IPOs, debt and equity financings and M&As for leading companies in Asia, the United States and Europe. In the last 10 years alone, Mr. Lin has led M&A transactions valued (in aggregate) in excess of US$20 billion and raised financings valued (in aggregate) at over US$40 billion. Since April 2018, Mr. Lin has served as a member of the Biotech Advisory Panel of the Hong Kong Stock Exchange. 
 
 Prior to Bank of America Merrill Lynch, Mr. Lin also worked at Credit Suisse as an investment banker in their Hong Kong, San Francisco and Los Angeles offices, and at O'Melveny & Myers LLP as a corporate attorney in their Los Angeles Office. Mr. Lin currently serves as a member of the Biotech Advisory Panel of the Stock Exchange of Hong Kong. Mr. Lin received a Bachelor of Sciences degree in Biological Sciences from the University of California at Davis and a Juris Doctor degree from The University of Chicago Law School.

Job Titles:

• Senior Vice President
• Senior Vice President of Hong Kong Exchanges

Mrs. Han is the Senior Vice President of Hong Kong Exchanges and Clearing Ltd., charging in promotion and education of primary market toward founders, investors and intermediary's agency. Mrs. Han has more than 10 years working experiences in financial industry. Prior of entering Hong Kong Exchanges and Clearing Ltd., She worked in A-share investment platform of Credit Suisse and UBS with the qualification of A-share sponsor representative and Chinese CPA (non-practicing). Mrs. Han has master degrees of Peking University and Xiamen University.